Literature DB >> 7666503

Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers.

S J Arrigo1, K Huffman.   

Abstract

Constructs were generated in which expression of human immunodeficiency virus type 1 (HIV-1) protease (PR) was placed under control of the HIV-1 long terminal repeat, thus requiring the HIV-1 Tat protein for expression of PR. The activity of PR was assessed by cotransfection with a construct producing a Gag substrate. Expression of PR as an intramolecular multimer resulted in a large increase in PR activity in comparison with the level obtained with the expression of PR as a monomer. A cytotoxic effect of PR expression was also exhibited by the constructs expressing PR multimers. CD4+ T-cell lines were generated with a construct producing PR as a linked tetramer and screened for PR activity and inducibility. The replication of HIV-1 in these cell lines was several orders of magnitude reduced in comparison with that in cell lines not expressing PR. Infection in these cell lines could be detected early after infection but disappeared over time. Infection of the PR-expressing cell lines could be increased several orders of magnitude by the addition of a specific inhibitor of PR, U75875 (Upjohn), after infection of the cells, demonstrating that the potent inhibition of HIV-1 replication in these cells was directly due to the expression of PR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666503      PMCID: PMC189494     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Retrovirus protease characterized as a dimeric aspartic proteinase.

Authors:  I Katoh; Y Ikawa; Y Yoshinaka
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

2.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins.

Authors:  P L Darke; R F Nutt; S F Brady; V M Garsky; T M Ciccarone; C T Leu; P K Lumma; R M Freidinger; D F Veber; I S Sigal
Journal:  Biochem Biophys Res Commun       Date:  1988-10-14       Impact factor: 3.575

3.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

4.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease.

Authors:  R A Kramer; M D Schaber; A M Skalka; K Ganguly; F Wong-Staal; E P Reddy
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

5.  Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease.

Authors:  S Erickson-Viitanen; J Manfredi; P Viitanen; D E Tribe; R Tritch; C A Hutchison; D D Loeb; R Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

6.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.

Authors:  P Ashorn; T J McQuade; S Thaisrivongs; A G Tomasselli; W G Tarpley; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

7.  Crystal structure of a retroviral protease proves relationship to aspartic protease family.

Authors:  M Miller; M Jaskólski; J K Rao; J Leis; A Wlodawer
Journal:  Nature       Date:  1989-02-09       Impact factor: 49.962

8.  HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.

Authors:  J A Zack; S J Arrigo; S R Weitsman; A S Go; A Haislip; I S Chen
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

9.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides.

Authors:  H G Kräusslich; R H Ingraham; M T Skoog; E Wimmer; P V Pallai; C A Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

View more
  14 in total

1.  Development of a novel screen for protease inhibitors.

Authors:  L Gillim; G L Gusella; J Vargas; D Marras; M E Klotman; A Cara
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease.

Authors:  A Bukovsky; H Göttlinger
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

4.  HIV-1 protease inhibits its homologous reverse transcriptase by protein-protein interaction.

Authors:  M Böttcher; F Grosse
Journal:  Nucleic Acids Res       Date:  1997-05-01       Impact factor: 16.971

5.  C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.

Authors:  Fu-Hsien Yu; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

6.  Coding sequences upstream of the human immunodeficiency virus type 1 reverse transcriptase domain in Gag-Pol are not essential for incorporation of the Pr160(gag-pol) into virus particles.

Authors:  Hsu-Chen Chiu; Szu-Yung Yao; Chin-Tien Wang
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

7.  Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.

Authors:  David E Ott; Lori V Coren; Elena N Chertova; Tracy D Gagliardi; Kunio Nagashima; Raymond C Sowder; Dexter T K Poon; Robert J Gorelick
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

8.  A single amino acid substitution in HIV-1 reverse transcriptase significantly reduces virion release.

Authors:  Chien-Cheng Chiang; Shiu-Mei Wang; Yen-Yu Pan; Kuo-Jung Huang; Chin-Tien Wang
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

9.  The nucleocapsid region of human immunodeficiency virus type 1 Gag assists in the coordination of assembly and Gag processing: role for RNA-Gag binding in the early stages of assembly.

Authors:  David E Ott; Lori V Coren; Teresa Shatzer
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production.

Authors:  Yen-Yu Pan; Shiu-Mei Wang; Kuo-Jung Huang; Chien-Cheng Chiang; Chin-Tien Wang
Journal:  PLoS One       Date:  2012-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.